Global Pull Incentives for Better Antibacterials: The UK Leads the Way.
作者信息
Outterson Kevin, Rex John H
机构信息
Boston University, 765 Commonwealth Ave, Boston, MA, 02215, USA.
F2G Limited, Eccles, Cheshire, UK.
出版信息
Appl Health Econ Health Policy. 2023 May;21(3):361-364. doi: 10.1007/s40258-023-00793-w. Epub 2023 Feb 11.
Abstract
摘要
相似文献
1
Global Pull Incentives for Better Antibacterials: The UK Leads the Way.全球推动研发更好抗菌药物的激励措施：英国走在前列。
Appl Health Econ Health Policy. 2023 May;21(3):361-364. doi: 10.1007/s40258-023-00793-w. Epub 2023 Feb 11.
2
Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.估算抗菌药物全球拉动激励措施的适当规模。
Health Aff (Millwood). 2021 Nov;40(11):1758-1765. doi: 10.1377/hlthaff.2021.00688.
3
Pull incentives for antibiotics get push from the UK.英国对抗生素的拉动激励措施受到推动。
Nat Rev Drug Discov. 2022 Jun;21(6):406. doi: 10.1038/d41573-022-00088-0.
4
Can the UK 'Netflix' Payment Model Boost the Antibacterial Pipeline?英国“网飞”式付费模式能否提振抗菌药物研发管线？
Appl Health Econ Health Policy. 2023 May;21(3):365-372. doi: 10.1007/s40258-022-00786-1. Epub 2023 Jan 17.
5
Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States.解决抗菌药物市场失灵的报销模式：法国、德国、瑞典、英国和美国的做法。
Health Policy. 2021 Mar;125(3):296-306. doi: 10.1016/j.healthpol.2020.11.015. Epub 2020 Dec 1.
6
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.推动抗菌药物研发的激励措施：抗微生物药物耐药性跨大西洋工作组的分析。
Clin Infect Dis. 2017 Oct 15;65(8):1378-1382. doi: 10.1093/cid/cix526.
7
A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.新型住院抗生素激励措施的观点：没有一刀切的解决方案。
J Law Med Ethics. 2018 Jun;46(1_suppl):59-65. doi: 10.1177/1073110518782916.
8
Financial incentives for bowel cancer screening: Results from a mixed methods study in the United Kingdom.财务激励措施在大肠癌筛查中的应用：来自英国混合方法研究的结果。
Br J Health Psychol. 2022 Sep;27(3):741-755. doi: 10.1111/bjhp.12570. Epub 2021 Nov 8.
9
Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.为抗生素相关创新提供融资拉动机制：欧洲的机遇。
Clin Infect Dis. 2020 Nov 5;71(8):1994-1999. doi: 10.1093/cid/ciaa153.
10
AMR - UK is leading the rest of the world.英国在抗菌药物耐药性方面领先世界其他国家。
Vet Rec. 2019 Mar 9;184(10):297. doi: 10.1136/vr.l1052.
引用本文的文献
1
Antibiotics re-booted-time to kick back against drug resistance.抗生素迎来新契机——是时候反击耐药性了。
NPJ Antimicrob Resist. 2025 May 30;3(1):47. doi: 10.1038/s44259-025-00096-1.
2
Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally.激励新型抗生素和诊断试剂进入市场的定价、采购和报销政策：全球 10 个国家的经验教训。
Appl Health Econ Health Policy. 2024 Sep;22(5):629-652. doi: 10.1007/s40258-024-00888-y. Epub 2024 Jun 5.
3
Small-Molecule Antibiotic Drug Development: Need and Challenges.小分子抗生素药物研发：需求与挑战。
ACS Infect Dis. 2023 Nov 10;9(11):2062-2071. doi: 10.1021/acsinfecdis.3c00189. Epub 2023 Oct 11.
4
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom.在英国，评估头孢他啶/阿维巴坦治疗严重需氧革兰氏阴性菌感染的经济价值属性。
Pharmacoeconomics. 2023 Dec;41(12):1657-1673. doi: 10.1007/s40273-023-01310-6. Epub 2023 Aug 16.
5
The effect of antibiotic usage on resistance in humans and food-producing animals: a longitudinal, One Health analysis using European data.抗生素使用对人类和食用动物的耐药性的影响：使用欧洲数据进行的纵向、One Health 分析。
Front Public Health. 2023 Jun 15;11:1170426. doi: 10.3389/fpubh.2023.1170426. eCollection 2023.
本文引用的文献
1
Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs.2016 - 19年新抗生素监管批准时的证据及成本：对美国食品药品监督管理局批准药物的队列研究
BMJ Med. 2022 Dec 12;1(1):e000227. doi: 10.1136/bmjmed-2022-000227. eCollection 2022.
2
Can the UK 'Netflix' Payment Model Boost the Antibacterial Pipeline?英国“网飞”式付费模式能否提振抗菌药物研发管线？
Appl Health Econ Health Policy. 2023 May;21(3):365-372. doi: 10.1007/s40258-022-00786-1. Epub 2023 Jan 17.
3
The antibiotic subscription model: fostering innovation or repackaging old drugs?抗生素订阅模式：是促进创新还是旧药重新包装？
Lancet Microbe. 2023 Jan;4(1):e2-e3. doi: 10.1016/S2666-5247(22)00235-X. Epub 2022 Sep 22.
4
Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.估算抗菌药物全球拉动激励措施的适当规模。
Health Aff (Millwood). 2021 Nov;40(11):1758-1765. doi: 10.1377/hlthaff.2021.00688.
5
Resetting the agenda for antibiotic resistance through a health systems perspective.从卫生系统角度重新规划应对抗生素耐药性的策略。
Lancet Glob Health. 2021 Jul;9(7):e1022-e1027. doi: 10.1016/S2214-109X(21)00163-7.
6
Social, cultural and economic aspects of antimicrobial resistance.抗菌药物耐药性的社会、文化和经济层面
Bull World Health Organ. 2020 Dec 1;98(12):823-823A. doi: 10.2471/BLT.20.275875.
7
An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019.美国 1980-2019 年抗菌药物研发趋势分析。
Clin Infect Dis. 2021 Dec 6;73(11):e4444-e4450. doi: 10.1093/cid/ciaa859.
8
Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.评估营利性公益公司作为抗生素开发和商业化的一种额外结构。
Transl Res. 2020 Jun;220:182-190. doi: 10.1016/j.trsl.2020.02.006. Epub 2020 Feb 20.
9
Designing development programs for non-traditional antibacterial agents.设计非传统抗菌药物的开发项目。
Nat Commun. 2019 Jul 31;10(1):3416. doi: 10.1038/s41467-019-11303-9.
10
Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.2005-2016 年对抗多药耐药菌的进展：现代非劣效性试验设计使抗生素在细菌耐药性流行之前得以开发。
Clin Infect Dis. 2017 Jul 1;65(1):141-146. doi: 10.1093/cid/cix246.
Zotero 插件